PharmEasy Pre-IPO shares can be purchased through Supremus Angel by completing investor KYC, placing a buy request, confirming share availability and price, and executing the transaction via off-market transfer to the investor’s demat account.
PharmEasy is a Mumbai-based digital health-care and e-pharmacy platform launched in 2015,
offering medicines, OTC health products, diagnostics, and tele-consultation through
a unified online marketplace.
PharmEasy Pre-IPO shares can be purchased through Supremus Angel by completing investor KYC, placing a buy request, confirming share availability and price, and executing the transaction via off-market transfer to the investor’s demat account.
No. PharmEasy remains unlisted, with Pre-IPO shares available through secondary market transactions. The company operates in digital healthcare, online pharmacy, diagnostics, and healthcare services.
PharmEasy operates a digital health ecosystem offering online medicine delivery, diagnostic services, and healthcare products supported by a technology-driven supply chain and logistics infrastructure.
There is no SEBI-mandated lock-in when purchasing PharmEasy unlisted shares via the secondary market. After IPO listing, standard SEBI lock-in norms typically apply—around 6 months for pre-IPO non-promoter shareholders and 18 months for promoters’ minimum holding.
PharmEasy unlisted shares usually trade between ₹5 – ₹10 per share depending on demand, liquidity, and private-market transactions.
To sell PharmEasy unlisted shares, investors must submit a Delivery Instruction Slip (DIS) to their depository participant authorizing an off-market transfer to the buyer’s demat account.
The minimum investment amount depends on the prevailing market price, lot size, and seller availability. Supremus Angel communicates the applicable ticket size prior to order confirmation.
If PharmEasy unlisted shares are sold within 24 months of purchase, gains are treated as short-term capital gains and taxed according to the investor’s applicable income tax slab.
If PharmEasy unlisted shares are held for more than 24 months, long-term capital gains are taxed at 20% with indexation benefits as per prevailing Indian income tax laws.
After listing, capital gains taxation depends on the holding period calculated from the listing date, and listed equity taxation rules applicable at that time will apply.
Investors can check credit of PharmEasy shares in their NSDL or CDSL demat account, where the shares appear under ISIN-wise holdings.
Typically, demat credit occurs within 1–2 working days after payment confirmation and completion of the off-market transfer process.
Supremus Angel ensures transaction integrity through verified seller sourcing, compliance checks, demat-based transfers, transparent pricing, and structured execution processes.
Valuation is influenced by revenue growth, unit economics, market share, sector outlook, funding history, peer comparisons, and future IPO expectations.
Shares are sourced from early investors, ESOP holders, and existing shareholders through approved secondary market transactions, subject to availability.
Investors can track PharmEasy updates through funding announcements, regulatory developments, financial performance disclosures, and healthcare sector news curated by Supremus Angel.
Required documents include PAN card, Aadhaar card, Client Master Report (CMR), and completed KYC documentation as per regulatory requirements.
Investors with a long-term investment horizon, understanding of digital healthcare dynamics, and comfort with unlisted market liquidity typically consider such investments.
